Brokerages Set Glaukos Corporation (NYSE:GKOS) Target Price at $127.42

Key Points

• Glaukos Corporation (NYSE:GKOS) has received an average analyst recommendation of "Moderate Buy", with ten analysts rating it as buy and one as strong buy.
• The stock's average target price is set at $127.42, while recent price targets range from $72.00 to $134.00.
• In its latest earnings report, Glaukos exceeded EPS estimates with a loss of ($0.24), and reported a 29.7% increase in revenue year-over-year.

Shares of Glaukos Corporation (NYSE:GKOS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $127.4167.

Several equities analysts have weighed in on the stock. Wells Fargo & Company raised their target price on shares of Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. UBS Group raised their target price on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. William Blair upgraded shares of Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. Zacks Research cut shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Mizuho set a $130.00 price target on shares of Glaukos in a research note on Thursday, July 31st.

Glaukos Stock Performance

Shares of Glaukos stock traded up $3.59 during trading on Monday, reaching $93.73. The company's stock had a trading volume of 758,743 shares, compared to its average volume of 668,875. The company has a 50-day moving average price of $95.00 and a two-hundred day moving average price of $97.54. The firm has a market cap of $5.38 billion, a PE ratio of -56.81 and a beta of 0.77. Glaukos has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The company had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. Glaukos's quarterly revenue was up 29.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. On average, analysts forecast that Glaukos will post -1.08 EPS for the current year.

Institutional Investors Weigh In On Glaukos

Several hedge funds have recently modified their holdings of GKOS. Wellington Management Group LLP lifted its position in Glaukos by 6.1% during the first quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier's stock valued at $225,460,000 after buying an additional 131,251 shares in the last quarter. State Street Corp lifted its position in Glaukos by 5.3% during the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier's stock valued at $215,914,000 after buying an additional 105,972 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Glaukos by 3.5% during the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier's stock valued at $206,503,000 after buying an additional 68,497 shares in the last quarter. Primecap Management Co. CA lifted its position in Glaukos by 50.0% during the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier's stock valued at $188,814,000 after buying an additional 609,523 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Glaukos by 9.5% during the second quarter. Geode Capital Management LLC now owns 1,330,593 shares of the medical instruments supplier's stock valued at $137,454,000 after buying an additional 115,529 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.